Kassiou M, Scheffel U A, Musachio J L, Stathis M, Dannals R F
Biomedicine and Health Program, Australian Nuclear Science and Technology Organisation, NSW, Sydney, Australia.
Life Sci. 1995;57(23):PL367-72. doi: 10.1016/0024-3205(95)02212-2.
[3H]A-69024 has been prepared as a radioligand for studying the dopamine D1 receptor. [3H]A-69024 binds to rat striatal membranes with a KD = 14.3 +/- 3.2 nM (mean +/- SEM; n = 3) and Bmax = 63.5 +/- 12.8 fmol/mg wet tissue (1.8 +/- 0.3 pmol/mg protein). This ligand binds to only one site with a Hill coefficient close to unity. The in vivo biodistribution of [3H]A-69024 showed a high uptake in the striatum (5.9% ID/g) at 5 min followed by clearance. As a measure of specificity, the striatum/cerebellar ratio reached a maximum of 6.7 at 30 min post-injection. Pre-treatment with the D1 antagonist R(+)SCH 23390 (1 mg/kg) reduced this ratio to unity. The dopamine antagonist (+)butaclamol and unlabeled A-69024 inhibited striatal uptake by 70 and 51%, respectively. Spiperone (D2/5-HT2A) and ketanserin (5-HT2A/5-HT2C) at doses of 1 mg/kg had no inhibitory effect on [3H]A-69024 uptake in the striatum; however, increased uptake of [3H]A-69024 by > 30% in the whole brain was observed. The selectivity and affinity of [3H]A-69024 suggests that this non-benzazepine radioligand may be useful for in vitro and in vivo studies of the dopamine D1 receptor.
[3H]A-69024已被制备为用于研究多巴胺D1受体的放射性配体。[3H]A-69024与大鼠纹状体膜结合,解离常数KD = 14.3±3.2 nM(平均值±标准误;n = 3),最大结合量Bmax = 63.5±12.8 fmol/mg湿组织(1.8±0.3 pmol/mg蛋白质)。该配体仅与一个位点结合,希尔系数接近1。[3H]A-69024的体内生物分布显示,注射后5分钟纹状体摄取量较高(5.9%注射剂量/克),随后清除。作为特异性的指标,注射后30分钟纹状体/小脑比值最高达到6.7。用D1拮抗剂R(+)SCH 23390(1毫克/千克)预处理可使该比值降至1。多巴胺拮抗剂(+)丁酰苯和未标记的A-69024分别抑制纹状体摄取70%和51%。剂量为1毫克/千克的螺哌隆(D2/5-HT2A)和酮色林(5-HT2A/5-HT2C)对[3H]A-69024在纹状体中的摄取没有抑制作用;然而,观察到全脑中[3H]A-69024的摄取增加超过30%。[3H]A-69024的选择性和亲和力表明,这种非苯并氮杂卓放射性配体可能对多巴胺D1受体的体外和体内研究有用。